Sarepta Invests $500M in Deal with Arrowhead for RNAi-Based Therapies and Pipeline Expansion

Sarepta's strategic partnership with Arrowhead Pharmaceuticals marks a significant expansion of its clinical and preclinical pipeline through a comprehensive licensing and equity deal. This agreement includes a $500 million upfront payment, a $325 million equity investment, and annual payments, targeting advancements in RNAi-based therapies for diseases such as muscular dystrophies, pulmonary fibrosis, and spinocerebellar ataxia 2 using Arrowhead's TRiM platform[1][3]. The collaboration grants Sarepta access to seven programs, comprising four clinical-stage treatments and three preclinical ones, with potential milestone payments reaching $10 billion, reflecting the deal's long-term prospects[3][4]. With a strategic emphasis on diversifying its portfolio beyond Duchenne muscular dystrophy, Sarepta aims to reinforce its market position while maintaining substantial financial strength, thus setting the stage for promising growth in the competitive biotech landscape[2].